Italia markets close in 7 hours 59 minutes
FTSE MIB
33.786,04 +153,33 (+0,46%) Dow Jones
37.753,31 -45,66 (-0,12%) Nasdaq
15.683,37 -181,88 (-1,15%) Nikkei 225
38.079,70 +117,90 (+0,31%) Petrolio
82,66 -0,03 (-0,04%) Bitcoin EUR
57.292,17 -2.248,18 (-3,78%)
UCB SA (UCBJF)
Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 10:52AM EDT
| Chiusura precedente | 126,05 |
| Aperto | 126,05 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 126,05 - 126,05 |
| Intervallo di 52 settimane | 69,70 - 126,05 |
| Volume | |
| Media Volume | 91 |
| Capitalizzazione | 24,065B |
| Beta (5 anni mensile) | 0,40 |
| Rapporto PE (ttm) | 67,41 |
| EPS (ttm) | 1,87 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 1,47 (1,17%) |
| Data ex dividendo | 26 apr 2024 |
| Stima target 1A | N/D |
GlobeNewswireClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno
© 2024 Yahoo. Tutti i diritti riservati.